In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Complete Remission (CR)
Timeframe: Day 29
Complete Remission (CR)
Timeframe: Day 64
Complete Response with Partial Count Recovery (CRh)
Timeframe: Day 29
Complete Response with Partial Count Recovery (CRh)
Timeframe: Day 64
Complete Remission incomplete (CRi)
Timeframe: Day 29
Complete Remission incomplete (CRi)
Timeframe: Day 64
Minimal Residual Disease Negativity (MRD-)
Timeframe: Day 29
Minimal Residual Disease Negativity (MRD-)
Timeframe: Day 64
Morphologic Relapse
Timeframe: Day 29
MRD Relapse
Timeframe: Day 29
Morphologic Relapse
Timeframe: Day 64
MRD Relapse
Timeframe: Day 64
Refractory
Timeframe: Day 29
Refractory
Timeframe: Day 64